サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1287562

コレラワクチン市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Cholera Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
コレラワクチン市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年03月18日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のコレラワクチン市場規模は、2022年に490万米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に11.1%の成長率（CAGR）を示し、2028年までに920万米ドルに達すると予測しています。

コレラは、汚染された食品や水を通じて広がる細菌感染によって引き起こされる腸の病気です。激しい下痢、脱水、腹痛、発熱、心拍数の上昇、皮膚の弾力性の低下、低血圧、筋肉のけいれん、口の中、喉、鼻、まぶたなどの粘膜の乾燥などを引き起こします。現在、世界的に公衆衛生上の脅威となっており、ワクチンによって予防することが可能です。コレラワクチンは、生きたコレラ菌を体内で少量暴露することで、病気に対する免疫の発達を助けるものです。経口投与、皮内または筋肉内注射で体内に投与することが可能です。

コレラワクチンの市場動向：

衛生環境の悪化に伴うコレラの蔓延が、市場を牽引する大きな要因の一つとなっています。また、世界各地で農業や花卉栽培のために汚染された水を使用することが増加しています。これは、個人の多忙なライフスタイルに起因するストリートフードやファーストフードの消費の増加とともに、市場の成長を後押ししています。さらに、下水や工場廃棄物が湖や川に流されることで、水質汚染も深刻化しています。その結果、人々は汚染された魚介類を摂取するようになり、コレラの蔓延を招いています。さらに、非政府組織（NGO）のイニシアティブによるコレラに対する意識の高まりや、ワクチンで予防できる病気を減らすために各国政府が導入した数多くの予防接種プログラムが、市場にプラスの影響を及ぼしています。さらに、主要な市場関係者は、より効率的で費用対効果の高いコレラワクチンを提供するために研究開発（R&D）活動に幅広く投資しており、これが市場の成長を促進すると予測されます。

本レポートで回答した主な質問

  • コレラワクチンの世界市場はこれまでどのように推移し、今後数年間はどのように推移するのでしょうか？
  • COVID-19は世界のコレラワクチン市場にどのような影響を与えたか？
  • 主要な地域市場とは？
  • ワクチンの種類に基づく市場の内訳は？
  • 製品に基づく市場の内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々なステージは何か？
  • 業界における主要な促進要因と課題は何か？
  • 世界のコレラワクチン市場の構造と主要企業は？
  • 業界における競合の程度はどの程度か？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 コレラワクチンの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 ワクチンタイプ別市場内訳

  • 全細胞型V. Cholerae O1 withリコンビナントB-サブユニット
    • 市場動向
    • 市場予測
  • キルドオーラルO1およびO139
    • 市場動向
    • 市場予測

第7章 製品別市場内訳

  • デュコラル
    • 市場動向
    • 市場予測
  • シャンコール
    • 市場動向
    • 市場予測
  • ヴァクスコラ
    • 市場動向
    • 市場予測
  • ユービコールとユービコールプラス
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 エンドユーザー別市場内訳

  • 病院・診療所
    • 市場動向
    • 市場予測
  • 研究機関・学術研究所
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 地域別市場内訳

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋地域
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 国別市場内訳
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Astellas Pharma Inc.
    • Celldex Therapeutics Inc.（Avant Immunotherapeutics Inc.）
    • Emergent BioSolutions Inc.
    • Eubiologics Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc
    • Pfizer Inc.
    • PharmaChoice Canada Inc
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited.
    • Valneva SE
図表

List of Figures

  • Figure 1: Global: Cholera Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Cholera Vaccines Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Cholera Vaccines Market: Breakup by Vaccine Type (in %), 2022
  • Figure 5: Global: Cholera Vaccines Market: Breakup by Product (in %), 2022
  • Figure 6: Global: Cholera Vaccines Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Cholera Vaccines Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Cholera Vaccines (Killed Oral O1 and O139) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Cholera Vaccines (Killed Oral O1 and O139) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Cholera Vaccines (Dukoral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Cholera Vaccines (Dukoral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Cholera Vaccines (Shanchol) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Cholera Vaccines (Shanchol) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Cholera Vaccines (Vaxchora) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Cholera Vaccines (Vaxchora) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Cholera Vaccines (Other Product) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Cholera Vaccines (Other Product) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Cholera Vaccines (Hospitals and Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Cholera Vaccines (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Cholera Vaccines (Research and Academic Laboratories) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Cholera Vaccines (Research and Academic Laboratories) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Cholera Vaccines (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Cholera Vaccines (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: North America: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: North America: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: United States: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: United States: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Canada: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Canada: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Asia-Pacific: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Asia-Pacific: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: China: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: China: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Japan: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Japan: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: India: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: India: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: South Korea: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: South Korea: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Australia: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Australia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Indonesia: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Indonesia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Europe: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Europe: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Germany: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Germany: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: France: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: France: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United Kingdom: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United Kingdom: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Italy: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Italy: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Spain: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Spain: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Russia: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Russia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Latin America: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Latin America: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Brazil: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Brazil: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Mexico: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Mexico: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Middle East and Africa: Cholera Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Middle East and Africa: Cholera Vaccines Market: Breakup by Country (in %), 2022
  • Figure 76: Middle East and Africa: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Global: Cholera Vaccines Industry: SWOT Analysis
  • Figure 78: Global: Cholera Vaccines Industry: Value Chain Analysis
  • Figure 79: Global: Cholera Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cholera Vaccines Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Cholera Vaccines Market Forecast: Breakup by Vaccine Type (in Million US$), 2023-2028
  • Table 3: Global: Cholera Vaccines Market Forecast: Breakup by Product (in Million US$), 2023-2028
  • Table 4: Global: Cholera Vaccines Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Cholera Vaccines Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Cholera Vaccines Market: Competitive Structure
  • Table 7: Global: Cholera Vaccines Market: Key Players
目次
Product Code: SR1623A320_Report

The global cholera vaccines market size reached US$ 4.9 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.2 Million by 2028, exhibiting a growth rate (CAGR) of 11.1% during 2023-2028.

Cholera is an intestinal disease caused by bacterial infections that spread through contaminated food and water. It leads to severe diarrhea, dehydration, abdominal pain, fever, rapid heart rate, loss of skin elasticity, low blood pressure, muscle cramps, and dry mucous membranes, such as the inside of the mouth, throat, nose, and eyelids. It is presently a global threat to public health, which can be prevented through the vaccine. The cholera vaccine exposes a small dose of live cholera bacteria in the body that helps develop immunity against the disease. It can be given orally or injected intradermally or intramuscularly in the body.

Cholera Vaccines Market Trends:

The growing prevalence of cholera on account of poor hygiene and sanitation represents one of the major factors driving the market. In addition, there is a rise in the use of contaminated water for agriculture and olericulture across the globe. This, along with the increasing consumption of street and fast food due to the hectic lifestyles of individuals, is propelling the growth of the market. Moreover, there is a considerable rise in water pollution on account of sewage and factory wastes getting discharged into lakes and rivers. As a result, people are consuming contaminated seafood worldwide, which, in turn, is resulting in the spread of cholera. Additionally, rising awareness about cholera through initiatives of non-governmental organizations (NGOs), along with numerous immunization programs introduced by governments of several countries to reduce vaccine-preventable diseases, is positively influencing the market. Furthermore, key market players are extensively investing in research and development (R&D) activities to provide more efficient and cost-effective cholera vaccines, which is projected to propel the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cholera vaccines market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on vaccine type, product and end user.

Breakup by Vaccine Type:

Whole Cell V. Cholerae O1 with Recombinant B-Subunit

Killed Oral O1 and O139

Breakup by Product:

Dukoral

Shanchol

Vaxchora

Euvichol and Euvichol-Plus

Others

Breakup by End User:

Hospitals and Clinics

Research and Academic Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Eubiologics Co. Ltd., Johnson & Johnson, Merck & Co. Inc, Pfizer Inc., PharmaChoice Canada Inc, Sanofi S.A., Takeda Pharmaceutical Company Limited and Valneva SE.

Key Questions Answered in This Report:

  • How has the global cholera vaccines market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global cholera vaccines market?
  • What are the key regional markets?
  • What is the breakup of the market based on the vaccine type?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cholera vaccines market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cholera Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Whole Cell V. Cholerae O1 with Recombinant B-Subunit
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Killed Oral O1 and O139
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Dukoral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Shanchol
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Vaxchora
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Euvichol and Euvichol-Plus
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research and Academic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Astellas Pharma Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Emergent BioSolutions Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eubiologics Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 PharmaChoice Canada Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Valneva SE
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials